MX2015015079A - Geles de nano-red inyectables para tratamiento de diabetes. - Google Patents

Geles de nano-red inyectables para tratamiento de diabetes.

Info

Publication number
MX2015015079A
MX2015015079A MX2015015079A MX2015015079A MX2015015079A MX 2015015079 A MX2015015079 A MX 2015015079A MX 2015015079 A MX2015015079 A MX 2015015079A MX 2015015079 A MX2015015079 A MX 2015015079A MX 2015015079 A MX2015015079 A MX 2015015079A
Authority
MX
Mexico
Prior art keywords
glucose
insulin
delivery
diabetes treatment
injectable nano
Prior art date
Application number
MX2015015079A
Other languages
English (en)
Inventor
Daniel G Anderson
Zhen Gu
Alex Arthur Aimetti
Robert S Langer
Original Assignee
Massachusetts Inst Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Inst Technology filed Critical Massachusetts Inst Technology
Publication of MX2015015079A publication Critical patent/MX2015015079A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A61K38/443—Oxidoreductases (1) acting on CH-OH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y40/00—Manufacture or treatment of nanostructures

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)

Abstract

Un sistema para suministro "inteligente" de un agente terapéutico, profiláctico o de diagnóstico, tal como el suministro de insulina mediado por glucosa a través de una nano-red inyectable que consiste de nanopartículas de dextrano opuestamente cargas que encapsulan insulina y enzimas específicas de glucosa que forman un estructura 3D similar al gel. Como se demuestra por los ejemplos, el sistema efectivamente se disocia para liberar insulina en una condición hiperglucémica, donde se facilitan la conversión catalítica de glucosa en ácido glucónico y la degradación subsecuente de la matriz polimérica. Este diseño de formulación proporciona una estrategia de suministro para el manejo de diabetes tanto auto- regulado como a largo plazo.
MX2015015079A 2013-04-30 2014-04-29 Geles de nano-red inyectables para tratamiento de diabetes. MX2015015079A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361817752P 2013-04-30 2013-04-30
US201361864069P 2013-08-09 2013-08-09
PCT/US2014/035927 WO2014179344A1 (en) 2013-04-30 2014-04-29 Injectable nano-network gels for diabetes treatment

Publications (1)

Publication Number Publication Date
MX2015015079A true MX2015015079A (es) 2016-07-05

Family

ID=51843897

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015015079A MX2015015079A (es) 2013-04-30 2014-04-29 Geles de nano-red inyectables para tratamiento de diabetes.

Country Status (11)

Country Link
US (1) US20160067190A1 (es)
EP (1) EP2991673A4 (es)
JP (1) JP2016517885A (es)
KR (1) KR20160024853A (es)
CN (1) CN105813652A (es)
AU (1) AU2014260024B2 (es)
BR (1) BR112015027561A8 (es)
HK (2) HK1221415A1 (es)
MX (1) MX2015015079A (es)
RU (1) RU2015151135A (es)
WO (1) WO2014179344A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014153114A1 (en) * 2013-03-14 2014-09-25 Fred Hutchinson Cancer Research Center Compositions and methods to modify cells for therapeutic objectives
EP3233174B1 (en) * 2014-12-19 2021-03-31 Kemin Industries, Inc. Intraocular delivery of bioactive molecules using iontophoresis
CN104740641B (zh) * 2015-04-08 2019-02-01 烟台大学 一种糖敏感的缓控释微球组合物及其制备方法
PE20180325A1 (es) * 2015-04-21 2018-02-13 Univ North Carolina State Sistema de suministro de insulina sensible a la glucosa usando nanocompuestos sensibles a la hipoxia
US11938216B2 (en) * 2016-07-21 2024-03-26 Boston Scientific Scimed, Inc. Injectable compositions
WO2018085809A1 (en) 2016-11-07 2018-05-11 North Carolina State University Patch loaded with dual-sensitive vesicles for enhanced glucose-responsive insulin delivery
DK3548135T3 (da) 2016-12-05 2021-11-22 Univ North Carolina State Kerne-skal-mikronålsindretninger og anvendelser deraf
CN106668840B (zh) * 2017-02-10 2020-02-14 南通大学 一种胰岛素控释药物及其制备方法与应用
CN111343970A (zh) * 2017-09-13 2020-06-26 北卡罗莱纳州立大学 微针贴片局部诱导脂肪组织褐变治疗肥胖症
CN111629746B (zh) * 2017-11-21 2024-04-16 北卡罗来纳州立大学 具有超快响应的用于葡萄糖触发胰岛素递送的电荷可切换聚合物储库
JP7381469B2 (ja) * 2018-01-03 2023-11-15 ザ、ペン、ステート、リサーチ、ファウンデーション 新生児抗痙攣薬としてのグルコースオキシダーゼ組成物
CN111195238A (zh) * 2018-10-31 2020-05-26 南方医科大学 一种用于胰岛素口服递送的聚电解质复合物
WO2020219880A2 (en) * 2019-04-25 2020-10-29 Massachusetts Institute Of Technology Cyclodextrin supramolecular scaffolds and uses thereof
CN115350267A (zh) * 2022-07-19 2022-11-18 深圳大学 一种级联催化型纳米治疗剂及其制备方法和应用
CN116474162B (zh) * 2023-04-28 2024-08-16 吉林大学 一种用于糖尿病慢性创伤修复的自修复水凝胶的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5359030A (en) * 1993-05-10 1994-10-25 Protein Delivery, Inc. Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same
WO1998000170A1 (en) * 1996-07-01 1998-01-08 Universiteit Utrecht Hydrolysable hydrogels for controlled release
CA2509382A1 (en) * 2002-12-17 2004-07-08 Todd C. Zion Stimuli-responsive systems for controlled drug delivery
WO2006088473A2 (en) * 2004-04-23 2006-08-24 Panduranga Rao Koritala Microcapsules and nanocapsules for the transmucosal delivery of therapeutic and diagnostic agents
EP1595534A1 (en) * 2004-05-13 2005-11-16 Universiteit Utrecht Holding B.V. Gel composition comprising charged polymers
TWI394580B (zh) * 2008-04-28 2013-05-01 Halozyme Inc 超快起作用胰島素組成物
KR20110028631A (ko) * 2008-07-01 2011-03-21 닛토덴코 가부시키가이샤 표면 피복 미립자의 의약 조성물

Also Published As

Publication number Publication date
US20160067190A1 (en) 2016-03-10
BR112015027561A2 (pt) 2017-07-25
HK1222546A1 (zh) 2017-07-07
EP2991673A4 (en) 2016-12-21
JP2016517885A (ja) 2016-06-20
CN105813652A (zh) 2016-07-27
RU2015151135A (ru) 2017-06-02
AU2014260024A1 (en) 2015-11-19
HK1221415A1 (zh) 2017-06-02
KR20160024853A (ko) 2016-03-07
EP2991673A1 (en) 2016-03-09
BR112015027561A8 (pt) 2019-12-24
WO2014179344A1 (en) 2014-11-06
AU2014260024B2 (en) 2016-09-15

Similar Documents

Publication Publication Date Title
MX2015015079A (es) Geles de nano-red inyectables para tratamiento de diabetes.
PH12017501910A1 (en) Glucose-responsive insulin delivery system using hyoxia-sensitive nanocomposites
BR112015005940A2 (pt) processo para a preparação de nanopartículas terapêuticas
BR112015005878A2 (pt) nanopartículas terapêuticas compreendendo agente terapêutico e métodos de preparar e usar as mesmas
WO2011163232A3 (en) Polypeptide electrospun nanofibrils of defined composition
WO2014093696A3 (en) Insulin derivatives for diabetes treatment
CA2867888C (en) Dually derivatized chitosan nanoparticles and methods of making and using the same for gene transfer in vivo
EP3970734A3 (en) Compartmentalized method of nucleic acid delivery and compositions and uses thereof
MX2012001204A (es) Composiciones de polimero de acido hialuronico modificado y metodos relacionados.
WO2010131916A3 (ko) siRNA 접합체 및 그 제조방법
WO2014165490A3 (en) Compositions of delivery systems for personal care products
BR112013007740A2 (pt) métodos para processamento de microesferas, microesferas processadas por tais métodos e seus usos
MY181626A (en) Treatment of diabetes mellitus by long-acting formulations of insulins
WO2013090523A3 (en) Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery
WO2012033835A3 (en) Devices for reducing the pain of glucose monitoring and insulin adminstration diabetic patients
MX2013005016A (es) Composiciones y métodos para la entrega de ácido nucleico a base de nanopolímeros.
NZ715595A (en) Treatment of disease with poly-n-acetyglucosamine nanofibers
NZ630385A (en) Beta-hydroxy-beta-methylbutyric acid for improving glucose tolerance
김현정 et al. New trends in skin barrier research
RS20150784A1 (sr) Dobijanje kompozitnih diskova hidrogelova polivinil alkohol/grafen sa inkorporisanim nanočesticama srebra
Choi et al. Super-Tough Hybridgels Comprising of Mesoporous Silica Microrods and Double-Network Polymers for On-Demand Drug Delivery by Mechanical Stimulation
CN204698740U (zh) 牙齿保持器
Bak Recent Advances in" Skin Barrier" Research
Santos In vivo assessment of the host reactions to natural origin biomaterials aimed to be used as wound dressers and as bone tissue engineering scaffolds
Ju et al. Long-term follow-up after loop electrosurgical excision procedure in high-grade cervical intraepithelial neoplasia